The Role of α1 and α6 Subtype Amino-Terminal Domains in Allosteric Regulation of γ-Aminobutyric Acida Receptors
- 1 October 1997
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 52 (4) , 714-724
- https://doi.org/10.1124/mol.52.4.714
Abstract
The γ-aminobutyric acidA (GABA) receptor in the mammalian central nervous system is composed of pentameric combinations of α1–6, β1–4, γ1–3, δ1, and/or ε1 subunit subtypes. Although each of the different subunits influences the functional properties of γ-aminobutyric acidA receptors (GABARs), the α subunit subtypes have been shown to be important for activation of the receptor by GABA and pentobarbital and the regulation of GABARs by numerous allosteric regulators, including benzodiazepines, furosemide, zinc, and lanthanum. However, with the exception of the benzodiazepines, the α subtype domain that is responsible for the action of these allosteric compounds is unknown. The α1 and α6 subtypes are among the most diverse of the α subunit family and confer a different responsiveness of GABARs to GABA and many of the allosteric modulators. These regulatory compounds act after extracellular application and therefore likely act on extracellular GABAR sites, the largest of which is the amino-terminal extracellular domain. To determine the role of this domain in the action of these allosteric regulatory agents, we constructed chimeras of the rat α1 and α6 subtypes with a splice site within the first putative transmembrane domain (TM). This separated the large extracellular amino-terminal domain from the transmembrane, intracellular, and TM2–3 and carboxyl-terminal extracellular domains of the subunit. The chimeric subtypes were expressed in L929 fibroblasts along with β3 and γ2L subtypes, and their pharmacological properties were determined with whole-cell electrophysiological recording. The α subtype amino-terminal extracellular domain was the primary determinant of GABA sensitivity and was responsible for the functional properties of activation by pentobarbital, sensitivity to diazepam, potentiation by lanthanum, and high affinity inhibition by furosemide. The remaining carboxyl-terminal domains influenced the GABA sensitivity and determined zinc sensitivity and low affinity inhibition by furosemide. Both domains were apparently required for inhibition by lanthanum.Keywords
This publication has 23 references indexed in Scilit:
- Alterations of the benzodiazepine site of rat α6β2γ2‐GABAA receptor by replacement of several divergent amino‐terminal regions with the αl counterpartsBritish Journal of Pharmacology, 1997
- Contrasting Actions of Lanthanum on Different Recombinant γ-Aminobutyric Acid Receptor Isoforms Expressed in L929 FibroblastsMolecular Pharmacology, 1997
- Expression of Functional GABAA Receptors in Transfected L929 Cells Isolated by Immunomagnetic Bead SeparationNeuropharmacology, 1997
- Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combinationBritish Journal of Pharmacology, 1996
- A single histidine residue is essential for zinc inhibition of GABA rho 1 receptorsJournal of Neuroscience, 1995
- GABAA receptor needs two homologous domains of the & beta;-subunit for activation by GABA but not by pentobarbitalNature, 1993
- Assembly of GABAA receptor subunits: analysis of transient single-cell expression utilizing a fluorescent substrate/marker gene techniqueJournal of Neuroscience, 1993
- Regulation of the Human Enkephalin Promoter by Two Isoforms of the Catalytic Subunit of Cyclic Adenosine 3′,5′-Monophosphate-Dependent Protein KinaseMolecular Endocrinology, 1991
- Cerebellar GABAA receptor selective for a behavioural alcohol antagonistNature, 1990
- High-efficiency transformation of mammalian cells by plasmid DNA.Molecular and Cellular Biology, 1987